Given that FXN overexpression is toxic, we developed a strategy to remove the GAA expansion mutation using CRISPR/Cas9 technology and dual guide RNA, resulting in increased FXN expression in FRDA patients’ CD34+ HSPCs12. The gene discussed is CD34; the disease is Friedreich ataxia.